scholarly journals Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ

Cancer ◽  
2006 ◽  
Vol 106 (10) ◽  
pp. 2113-2118 ◽  
Author(s):  
R. Barry Hird ◽  
Alfred Chang ◽  
Vincent Cimmino ◽  
Kathleen Diehl ◽  
Michael Sabel ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Receptor Expression ◽  
Estrogen Receptor Expression ◽  
Clinicopathologic Features

Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens

2016 ◽  
Vol 40 (8) ◽  
pp. 1090-1099 ◽  
Author(s):  
Christopher J. VandenBussche ◽  
Ashley Cimino-Mathews ◽  
Ben Ho Park ◽  
Leisha A. Emens ◽  
Theodore N. Tsangaris ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Ductal Carcinoma In Situ ◽  
Core Biopsy ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Needle Core Biopsy ◽  
Biopsy Specimens

scholarly journals Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ

The Breast ◽  
2011 ◽  
Vol 20 (6) ◽  
pp. 529-533 ◽  
Author(s):  
Anna F. Meyerson ◽  
Juan N. Lessing ◽  
Kaoru Itakura ◽  
Nola M. Hylton ◽  
Dulcy E. Wolverton ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Active Surveillance ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Estrogen Receptor Positive

scholarly journals Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer

ISRN Oncology ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Andrei Dobrescu ◽  
Monique Chang ◽  
Vatsala Kirtani ◽  
George K. Turi ◽  
Randa Hennawy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma In Situ ◽  
Invasive Breast Cancer ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Receptor Expression ◽  
Invasive Cancer ◽  
Positive Staining ◽  
Receptor Status

Background. To our knowledge, the hormone receptor status of noncontiguous ductal carcinoma in situ (DCIS) occurring concurrently in ER/PgR-negative invasive cancer has not been studied. The current study was undertaken to investigate the ER/PgR receptor status of DCIS of the breast in patients with ER/PgR-negative invasive breast cancer. Methods. We reviewed the immunohistochemical (IHC) staining for ER and PgR of 187 consecutive cases of ER/PgR-negative invasive breast cancers, collected from 1995 to 2002. To meet the criteria for the study, we evaluated ER/PgR expression of DCIS cancer outside of the invasive breast cancer. Results. A total of 37 cases of DCIS meeting the above criteria were identified. Of these, 16 cases (43.2%) showed positive staining for ER, PgR, or both. Conclusions. In our study of ER/PgR-negative invasive breast cancer we found that in 8% of cases noncontiguous ER/PR-positive DCIS was present. In light of this finding, it may be important for pathologists to evaluate the ER/PgR status of DCIS occurring in the presence of ER/PgR-negative invasive cancer, as this subgroup could be considered for chemoprevention.

Sign in / Sign up

Export Citation Format

Share Document